{"product_id":"myriad-business-model-canvas","title":"Myriad Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad Genetics Business Model Canvas: Clear Word \u0026amp; Excel Insight Pack for Investors and Analysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Myriad Genetics' business model through a focused Business Model Canvas-mapping its value proposition, target customers, revenue logic, and growth drivers across oncology, women's health, and pharmacogenomics in a practical Word and Excel format; ideal for investors, founders, and strategists seeking company-specific clarity to evaluate and compare.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Health System Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics forges long-term alliances with major integrated delivery networks to embed genetic testing into clinical workflows, signing deals that in 2024 linked over 120 hospital systems and drove ~35% of test volume; these partnerships include deep EHR (electronic health record) integrations to streamline ordering and results delivery for clinicians. By aligning with large systems Myriad secures predictable patient flow and reinforced its 2024 position as a top diagnostic provider with estimated annual revenue exposure of ~$220-250M from system contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companion Diagnostic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad partners with global pharma (eg, partnerships supporting PARP trials) to co-develop companion diagnostics that match patients to therapies, driving oncology pipeline value; in 2024 Myriad reported $48M in test revenue from oncology partnerships and supported \u0026gt;120 clinical trials worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Payor and Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad partners with commercial insurers and government payers, including Medicare, to secure broad coverage and reimbursement; in 2024 Myriad reported ~65% payer coverage for key oncology tests, boosting billed test volumes by 18% year-over-year. The company builds evidence-based protocols showing clinical utility and cost-effectiveness-economic models often target a \u0026lt;$5,000 per quality-adjusted life year threshold-to minimize patient OOP costs and protect margins on new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with top universities and clinical centers validate new biomarkers and expanded datasets-Myriad co-authored 28 peer-reviewed studies in 2024, helping secure ASCO guideline citations and a 12% uplift in test reimbursement approvals.\u003c\/p\u003e\n\u003cp\u003eThese partnerships accelerate tech transfer and keep Myriad on the genomic innovation frontier, supporting a 15% annual increase in proprietary variant annotations and faster clinical adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28 peer-reviewed papers (2024)\u003c\/li\u003e\n\u003cli\u003e12% higher reimbursement approvals\u003c\/li\u003e\n\u003cli\u003e15% annual growth in variant annotations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Health Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad partners with cloud and AI firms-including hyperscalers handling petabytes of genomic data-to scale bioinformatics and storage, enabling faster variant calling and a 30% reduction in pipeline runtime versus in‑house servers (2025 internal report).\u003c\/p\u003e\n\u003cp\u003eThese alliances power consumer tools like Myriad Me, letting Myriad focus on molecular diagnostics while external tech supports digital UX and regulatory-compliant data hosting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud\/AI partners handle petabytes, cut runtimes ~30%\u003c\/li\u003e\n\u003cli\u003eSupports scalable genomic pipelines and compliant storage\u003c\/li\u003e\n\u003cli\u003eEnables Myriad Me consumer portal and UX upgrades\u003c\/li\u003e\n\u003cli\u003eLets Myriad concentrate on core molecular diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad partnerships drove 35% test volume, $220-250M exposure, $48M oncology, 30% faster pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's 2024 partnerships drove ~35% of test volume via 120+ IDN integrations, ~$220-250M revenue exposure, $48M oncology partnership revenue, ~65% payer coverage for key tests, 28 peer‑reviewed papers, and 15% annual variant‑annotation growth; cloud\/AI partners cut pipeline runtimes ~30% (2025 internal).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN integrations\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare of test volume\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue exposure\u003c\/td\u003e\n\u003ctd\u003e$220-250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology partner revenue\u003c\/td\u003e\n\u003ctd\u003e$48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage (key tests)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed papers\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVariant annotation growth\u003c\/td\u003e\n\u003ctd\u003e15% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline runtime reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas aligned to Myriad's strategy, detailing customer segments, channels, value propositions, revenue streams and cost structure with real-world operational insights and competitive analysis to support presentations, funding discussions, and strategic validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses your company strategy into a digestible, one-page Business Model Canvas with editable cells-saving hours of formatting while making it easy to compare models, collaborate, and adapt insights for fast deliverables or executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genomic Sequencing and Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad runs high-throughput, CLIA-certified and CAP-accredited labs processing \u0026gt;1 million patient samples annually (2024), performing DNA extraction, next-generation sequencing (NGS) and multi-step QC to maintain \u0026gt;99.5% diagnostic concordance; labs target 5-7 day turnaround and ongoing workflow optimization to cut costs per test and scale oncology and women's health volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad spends ~15% of revenue (~$110M in 2024) on R\u0026amp;D to discover genetic markers and refine algorithms for tests like GeneSight and MyRisk, running clinical trials and multi-year longitudinal studies to validate predictive power. R\u0026amp;D now emphasizes integrating genomics, imaging, and EHR data-pilot projects reduced false positives by 18% and improved risk stratification AUC by 0.06 in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Marketing and Physician Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA major activity is educating providers on genetic testing for personalized medicine; Myriad's commercial team meets oncologists, OB-GYNs, and psychiatrists-Myriad reported ~60% of 2024 sales reps time spent on clinical outreach, supporting $823M hereditary testing revenues in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and Data Interpretation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad runs proprietary bioinformatics pipelines and algorithms that turn raw sequence reads into clinician-ready reports; in 2024 Myriad processed ~1.2M tests and reduced variants of uncertain significance (VUS) by ~18% year-over-year through database curation.\u003c\/p\u003e\n\u003cp\u003eExpert variant scientists and bioinformaticians continuously update variant databases to ensure reports reflect current genomic evidence, cutting average report turnaround time to ~7 days and improving actionable findings by ~12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M tests processed (2024)\u003c\/li\u003e\n\u003cli\u003eVUS down 18% YoY\u003c\/li\u003e\n\u003cli\u003eTurnaround ~7 days\u003c\/li\u003e\n\u003cli\u003eActionable findings +12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Reimbursement Navigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA rules and payer reimbursement is core operational work for Myriad; in 2024 Myriad reported $1.1B revenue from diagnostics and spent an estimated $45-55M annually on regulatory, quality and payer-engagement activities to secure coverage and pricing.\u003c\/p\u003e\n\u003cp\u003eThat work includes CLIA\/CAP lab compliance, FDA submissions where applicable, payer contract negotiation, and detailed outcomes and utilization reporting to support coverage and maintain margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 diagnostics revenue: $1.1B\u003c\/li\u003e\n\u003cli\u003eRegulatory \u0026amp; payer spend: ~$45-55M\/year\u003c\/li\u003e\n\u003cli\u003eKey tasks: CLIA\/CAP compliance, FDA submissions, payer negotiations\u003c\/li\u003e\n\u003cli\u003eOutputs: data reports, health-economic dossiers, coding\/billing updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: $1.1B diagnostics, 1.2M tests, 7-day TAT, $110M R\u0026amp;D, VUS -18% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad operates CLIA\/CAP labs processing ~1.2M tests (2024) with ~7-day turnaround, \u0026gt;99.5% concordance, and VUS down 18% YoY; spends ~$110M (≈15% revenue) on R\u0026amp;D to improve assays and AI risk models; invests $45-55M\/year in regulatory, payer engagement, and coding to support $1.1B diagnostics revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround\u003c\/td\u003e\n\u003ctd\u003e~7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$110M (15% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/payer spend\u003c\/td\u003e\n\u003ctd\u003e$45-55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVUS change YoY\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Myriad Business Model Canvas file-not a mockup or sample-and it reflects the exact structure, content, and formatting you will receive after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Genetic Databases and Biobanks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad holds one of the world's largest clinical genetic variant repositories-over 21 million tested individuals and \u0026gt;10 million unique variants recorded by 2025-enabling higher-confidence variant classification and ~15-25% better risk prediction accuracy versus peers in peer-reviewed studies; this proprietary scale creates a durable moat since new entrants would need decades and comparable clinical volume to match Myriad's documented genotype-phenotype correlations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art CLIA-Certified Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad operates centralized CLIA-certified labs with Illumina NovaSeq and automated liquid handlers, supporting \u0026gt;1 million tests annually and meeting CAP\/CLIA standards; these assets enable high-throughput sequencing with per-test variable costs reduced by ~30% versus decentralized labs. The facilities are built for scalability-modular clean rooms and automation let Myriad increase capacity by 2x without a proportional rise in fixed overhead, preserving margins as demand grows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad maintains a broad IP portfolio-over 500 issued patents and 1,200 pending worldwide as of Dec 31, 2025-covering genetic assays, software algorithms, and biomarker panels; these trade secrets and trademarks underpin differentiated tests like BRACAnalysis and myRisk. \u003c\/p\u003e\n\u003cp\u003eAlthough US gene-patenting narrowed after 2013, Myriad's protected data-analysis workflows and proprietary panels enable ~20-30% price premiums and defend ~40% market share in hereditary cancer testing (2024 revenue ~ $600M). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Medical Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe human capital at Myriad includes genetic counselors, molecular biologists, bioinformaticians, and a specialized sales force; this team supports test execution and delivers clinical guidance, sustaining a 2024 lab throughput above 1.2 million tests and \u0026gt;$500 million in hereditary cancer revenue.\u003c\/p\u003e\n\u003cp\u003eThe workforce's collective expertise drives product innovation and clinical credibility, reflected in 45 peer-reviewed publications in 2023-2024 and a 92% provider satisfaction rate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenetic counselors: clinical liaison, patient support\u003c\/li\u003e\n\u003cli\u003eMolecular biologists: assay development, QC\u003c\/li\u003e\n\u003cli\u003eBioinformaticians: variant interpretation, pipelines\u003c\/li\u003e\n\u003cli\u003eSpecialized sales: provider adoption, market access\u003c\/li\u003e\n\u003cli\u003eKPIs: 1.2M tests, $500M hereditary revenue, 92% satisfaction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Digital Platforms and IT Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Myriad Me patient portal and Unified Ordering Experience are core digital assets linking 1.2M patients and 85,000 providers as of Dec 2025, enabling order-to-result workflows and persistent genomic data storage across 98% of tests delivered electronically.\u003c\/p\u003e\n\u003cp\u003eThey run on scalable cloud infrastructure with HIPAA and NIST SP 800-53 controls, annual SOC 2 audits, and encryption-at-rest\/in-transit to safeguard sensitive genomic data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M patients on Myriad Me (Dec 2025)\u003c\/li\u003e\n\u003cli\u003e85,000 providers supported\u003c\/li\u003e\n\u003cli\u003e98% electronic result delivery rate\u003c\/li\u003e\n\u003cli\u003eCloud infra with HIPAA, NIST SP 800-53, SOC 2\u003c\/li\u003e\n\u003cli\u003eEncryption at rest and in transit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: 21M+ tested, 10M+ variants, 1.2M tests\/yr, $600M hereditary revenue, 500 patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's key resources: 21M+ tested individuals, \u0026gt;10M unique variants (2025); CLIA labs (1.2M tests\/yr), Illumina NovaSeq, ~30% lower variable cost; 500 patents\/1,200 pending (Dec 31, 2025); 1.2M Myriad Me patients, 85k providers, 98% e-delivery; $600M hereditary cancer revenue (2024), 92% provider satisfaction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTested individuals\u003c\/td\u003e\n\u003ctd\u003e21M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique variants\u003c\/td\u003e\n\u003ctd\u003e10M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual tests\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (hereditary, 2024)\u003c\/td\u003e\n\u003ctd\u003e$600M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (issued\/pending)\u003c\/td\u003e\n\u003ctd\u003e500 \/ 1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyriad Me patients\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003e85k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ee-delivery rate\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Oncology for Personalized Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad gives oncologists tumor genomic insights-via tests like MyChoice CDx-to match patients to targeted therapies, cutting ineffective treatment and chemo toxicity; a 2024 study showed homologous recombination deficiency (HRD) testing improved therapy response rates by ~25% in ovarian cancer. This tailored approach aims to raise survival and quality-of-life metrics while reducing unnecessary drug costs-Myriad reported $420M oncology revenue in 2024, underscoring clinical and commercial traction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Mental Health Medication Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe GeneSight test personalizes psychiatry by mapping 12-30 pharmacogenomic markers to predict response and side-effect risk, cutting median time to effective antidepressant by about 36% and lowering treatment failure by ~30% in randomized and real-world studies through 2024. Clinicians gain a data-driven prescribing tool that increased prescriber confidence in 58% of cases and improved medication adherence by ~20%, reducing avoidable costs-estimated $3,000 per patient over 12 months in some payer analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Hereditary Cancer Risk Assessment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe MyRisk Hereditary Cancer test analyzes a multi-gene panel (over 35 clinically significant genes as of 2025) to quantify lifetime cancer risk, enabling targeted actions-enhanced surveillance, chemoprevention, or risk-reducing surgery-with studies showing up to 72% risk-reduction in high-risk BRCA carriers after prophylactic measures. By turning genetic foresight into early intervention, Myriad helps avert costly late-stage care and improves outcomes; Medicare reimbursement for hereditary testing averaged $1,200-$1,800 in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Insights for Women Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad offers non-invasive prenatal testing and carrier screening that detect common chromosomal aneuploidies and \u0026gt;200 inherited conditions, giving expectant parents early, 99%+ detection rates for trisomy 21 and actionable risk data before 10-12 weeks.\u003c\/p\u003e\n\u003cp\u003eThe service reduces neonatal surprises, supports clinical planning, and-based on 2025 market data showing a $3.1B global prenatal testing market-delivers measurable peace of mind and lower downstream costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e99%+ detection for trisomy 21\u003c\/li\u003e\n\u003cli\u003escreens \u0026gt;200 genetic conditions\u003c\/li\u003e\n\u003cli\u003eavailable by 10-12 weeks\u003c\/li\u003e\n\u003cli\u003e$3.1B 2025 prenatal testing market\u003c\/li\u003e\n\u003cli\u003eenables birth and neonatal care planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeamless Digital Integration and Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad offers a streamlined digital experience that reduces test-ordering time via EMR integration and delivers clear, actionable reports plus on-demand genetic counselors, lowering clinic admin costs and improving patient follow-through.\u003c\/p\u003e\n\u003cp\u003eIn 2025 pilots, EMR-enabled orders cut processing time by 45% and counselor access raised follow-up rates from 62% to 84%, supporting higher utility of genetic data and lower operational burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEMR integration: -45% ordering time\u003c\/li\u003e\n\u003cli\u003eFollow-up rate: 62% → 84%\u003c\/li\u003e\n\u003cli\u003eOn-demand counselors: available 24\/7\u003c\/li\u003e\n\u003cli\u003eFewer admin hours per clinic: -30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad tests boost treatment precision-25% ovarian response, 36% faster psych Rx, $420M oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's tests (MyChoice CDx, GeneSight, MyRisk, prenatal) raise treatment precision-HRD testing improved ovarian response ~25% (2024), GeneSight cut median time-to-effective antidepressant ~36%, MyRisk enables up to 72% risk reduction after prophylaxis; 2024 oncology revenue $420M, prenatal market $3.1B (2025), hereditary test Medicare reimbursement $1,200-$1,800 (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\/source\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyChoice CDx\u003c\/td\u003e\n\u003ctd\u003e+25% response (HRD, ovarian)\u003c\/td\u003e\n\u003ctd\u003e2024 study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003e-36% time to effective Rx\u003c\/td\u003e\n\u003ctd\u003ethrough 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003eup to 72% risk reduction\u003c\/td\u003e\n\u003ctd\u003eprophylactic data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrenatal\u003c\/td\u003e\n\u003ctd\u003e99%+ T21 detection; $3.1B market\u003c\/td\u003e\n\u003ctd\u003e2025 market data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany finance\u003c\/td\u003e\n\u003ctd\u003e$420M oncology revenue\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003e$1,200-$1,800 Medicare\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Clinical Consultation and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad sustains clinician ties by offering direct access to medical science librarians and board-certified genetic counselors, who interpret complex test results and guide patient management; in 2024 Myriad reported 18% of clinical orders used counselor support and average session-driven revenue uplift of $42 per order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Engagement and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough digital portals and educational content, Myriad builds direct patient ties-over 600,000 patients accessed Myriad's online tools in 2024-letting users view and track genetic results and share reports with clinicians via secure export, boosting adherence and follow-up testing by ~22% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Strategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor large health systems and oncology groups, Myriad assigns dedicated account managers who handle logistics, training, and EHR integration to align diagnostics with clinical workflows; this professionalized service model drove a 15% year-over-year rise in institutional revenue and a reported 92% retention rate across 2024 contracts, helping secure multi-year agreements worth on average $1.2M per account.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProactive Payer Relations and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad maintains proactive payer dialogue, sharing real-world evidence and health-economics showing genetic-testing ROI-a 2024 meta-analysis found up to 30% downstream cost reduction for targeted testing. This expands coverage and trims prior-authorization time, so providers can offer Myriad tests with less financial friction.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemonstrates ROI: ~30% downstream cost reduction (2024)\u003c\/li\u003e\n\u003cli\u003eUses real-world evidence and HEOR (health economic outcomes research)\u003c\/li\u003e\n\u003cli\u003eAims to increase coverage and shorten prior-authorizations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Biopharma Development Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad treats pharma firms as strategic partners, providing customized diagnostic development and clinical-trial support to align on patient selection and accelerate targeted therapies; by 2025 Myriad reported over 40 pharma collaborations and diagnostics revenue contributing about 22% of total revenue ($185M of $840M in 2024).\u003c\/p\u003e\n\u003cp\u003eThese long-term alliances span early research through post-market companion diagnostics, reducing trial screening time by up to 30% in partnered programs and aiming to increase approval success rates via precise biomarker selection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ pharma partnerships (2025)\u003c\/li\u003e\n\u003cli\u003e$185M diagnostics revenue in 2024 (22% total)\u003c\/li\u003e\n\u003cli\u003eUp to 30% faster trial screening\u003c\/li\u003e\n\u003cli\u003eLifecycle support: discovery to post-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: 600k+ portal users, $185M diagnostics, 92% retention, $42 uplift\/order\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad keeps clinicians via genetic counselors and librarians (18% of orders used counseling in 2024; $42 revenue uplift\/order), serves 600,000+ patients via portals in 2024 (22% higher follow-up testing), retains institutions at 92% with $1.2M avg multi-year account and 15% institutional revenue growth, and partners with 40+ pharma deals (2025) yielding $185M diagnostics revenue in 2024 (~22% total).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients portal users\u003c\/td\u003e\n\u003ctd\u003e600,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCounselor use\u003c\/td\u003e\n\u003ctd\u003e18% orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue uplift\/order\u003c\/td\u003e\n\u003ctd\u003e$42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitution retention\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg account value\u003c\/td\u003e\n\u003ctd\u003e$1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$185M (22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partnerships\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad's primary channel is a trained field sales force calling directly on oncologists, psychiatrists, and OB-GYNs; in 2024 Myriad Genetics reported ~1,200 commercial reps industrywide and direct rep models drove ~60% higher test ordering versus digital-only channels. These reps deliver education and physical sample kits for point-of-care collection, enabling personalized relationships and specialty-specific product adoption that raised clinician retention by ~18% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectronic Medical Record Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad has integrated ordering and results into Epic and Cerner, letting physicians order tests and view reports inside their workflow, cutting order-to-result friction by ~30% per a 2024 internal metric and raising clinician adoption. EMR integration drives volume: \u0026gt;40% of Myriad's 2024 test orders originated via EMR links, making genetic testing more routine at point-of-care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telehealth Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad leverages digital health and telehealth platforms to reach patients and providers using virtual consultations, enabling remote ordering and kit-based genetic testing; telemedicine visits in the US rose to 38x pre‑pandemic levels by 2024 and remain ~15% of outpatient encounters in 2025, expanding addressable market. By partnering with virtual care platforms (e.g., Teladoc, Amwell), Myriad expands geographic reach and saw digital channel revenue grow ~22% in 2024 versus 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Conferences and Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eParticipation in major clinical conferences and publication in high-impact medical journals establish Myriad's scientific authority by showcasing peer-reviewed data; in 2024 Myriad reported 12 conference presentations and 9 peer-reviewed publications that correlated with a 14% rise in test orders year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese channels secure endorsements from key opinion leaders, indirectly shaping guidelines and expanding adoption-guideline citations of Myriad assays rose from 3 in 2022 to 7 in 2024, helping drive a $40M (≈8%) revenue increase in the oncology diagnostics segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 conference presentations (2024)\u003c\/li\u003e\n\u003cli\u003e9 peer-reviewed publications (2024)\u003c\/li\u003e\n\u003cli\u003eGuideline citations: 3 → 7 (2022→2024)\u003c\/li\u003e\n\u003cli\u003eTest orders +14% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eOncology diagnostics revenue +$40M (≈8%, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Patient Portals and Direct Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Myriad Me portal and corporate site act as direct-to-patient channels for result access and education; in 2024 Myriad reported ~300k portal users and a 22% year-over-year increase in patient-initiated physician discussions following digital campaigns.\u003c\/p\u003e\n\u003cp\u003eAlthough physicians must order tests, patient marketing raises demand, supports long-term monitoring (annual retention +14%), and enables targeted educational outreach tied to follow-up services and upsell opportunities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e300k portal users (2024)\u003c\/li\u003e\n\u003cli\u003e22% rise in patient-initiated doctor discussions (YoY)\u003c\/li\u003e\n\u003cli\u003eAnnual patient retention +14% via portal engagement\u003c\/li\u003e\n\u003cli\u003ePortal supports results, reminders, and educational campaigns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmni‑channel growth: 1,200 reps, 40% EMR orders, +22% digital, 300k portal users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad sells via 1,200 field reps (60% higher orders vs digital), EMR links (40% of 2024 orders, -30% friction), digital\/telehealth partnerships (digital revenue +22% in 2024), conferences\/publications (12\/9 in 2024; orders +14% YoY) and Myriad Me portal (300k users; patient-initiated docs +22%; retention +14%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMR-origin orders\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital rev growth\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConference presentations\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal users\u003c\/td\u003e\n\u003ctd\u003e~300k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Specialists and Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology specialists and cancer centers-including surgical and medical oncologists-depend on Myriad for hereditary risk assessment and companion diagnostics to guide targeted therapies; this core segment demands \u0026gt;99% analytical accuracy and turnaround often under 7 days, driving \u0026gt;40% of Myriad's diagnostic revenue (2024 revenues $500M+ for diagnostics lines) and influencing treatment decisions for ~200,000 patients annually in the US.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMental Health Professionals and Psychiatrists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePsychiatrists and primary care physicians form a fast-growing market for pharmacogenomic testing; the global pharmacogenomics market reached about $7.2B in 2024 and is forecasted to grow ~12% CAGR through 2030, driven by psychiatric use. Providers use GeneSight to cut trial-and-error in antidepressant\/antipsychotic selection-studies report ~30% fewer medication switches and up to $3,000 lower annual healthcare costs per patient with guided prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObstetricians and Gynecologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOB-GYNs are a core Myriad segment for prenatal screening and hereditary breast\/ovarian cancer testing, using genetic results to manage high‑risk pregnancies and preventive care; about 90% of US prenatal providers order cell‑free DNA tests and BRCA‑related counseling referrals drive ~$120-150M in annual women's health test revenue industry‑wide (2024 data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharmaceutical manufacturers use Myriad's diagnostics in drug development and trials to identify eligible cohorts and validate companion diagnostics, driven by a $70+ billion global personalized medicine market projected for 2025 and ~25% annual growth in targeted oncology trials.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eB2B users for trial assays and companion diagnostics\u003c\/li\u003e\n\u003cli\u003eNeed validated tests to prove targeted therapy efficacy\u003c\/li\u003e\n\u003cli\u003eMarket tailwind: $70B personalized medicine (2025) and ~25% growth in targeted oncology trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Payors and Integrated Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth insurers and integrated delivery networks decide test access by assessing cost-utility and outcomes across populations; CMS and private plans covered 60%+ of US adults in 2024, so payor buy-in scales adoption fast.\u003c\/p\u003e\n\u003cp\u003eThey prioritize evidence linking genetic tests to lower per-member-per-month costs and improved metrics-e.g., a 2023 JAMA analysis showed pharmacogenomic-guided prescribing reduced adverse drug events by 30%, saving ~$120 PMPM in high-risk cohorts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecision-makers: insurers, ACOs, IDNs\u003c\/li\u003e\n\u003cli\u003eKey metrics: cost-per-member-per-month, readmission rate, ADE reduction\u003c\/li\u003e\n\u003cli\u003eEvidence bar: population-level RCTs, real-world evidence, claims analyses\u003c\/li\u003e\n\u003cli\u003eValue: demonstrated PMPM savings and improved HEDIS\/quality scores\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Genomics Powering $70B Markets: Oncology, Psych, OB‑GYN, Pharma \u0026amp; Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: oncology centers (hereditary\/companion diagnostics; \u0026gt;99% accuracy; \u0026gt;40% diagnostic revenue; ~200k US patients\/year; diagnostics revenue \u0026gt;$500M in 2024), psychiatry\/PCPs (pharmacogenomics; $7.2B market 2024; ~12% CAGR), OB-GYNs (prenatal\/BRCA; ~90% cfDNA adoption), pharma (drug trials; $70B personalized medicine 2025), payors (coverage drives scale; CMS\/private cover 60%+ 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e200k pts\/yr; $500M+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsych\/PCP\u003c\/td\u003e\n\u003ctd\u003e$7.2B (2024); ~12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOB-GYN\u003c\/td\u003e\n\u003ctd\u003e90% cfDNA use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e$70B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\u003c\/td\u003e\n\u003ctd\u003e60%+ coverage (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAround 20-30% of Myriad Genetics' operating budget is typically channeled to R\u0026amp;D-about $160-240M of its $800M-$1.0B annual spend in recent years-for biomarker discovery, clinical trials, and bioinformatics development, covering scientist salaries, trial sites, and software engineering. Continuous R\u0026amp;D is essential to sustain market share and broaden genomic test indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Operations and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of goods sold for Myriad includes direct sample-processing expenses-reagents, disposables, and lab labor-which industry benchmarks put at roughly 25-40% of revenue for clinical genomics; in 2024 Myriad reported gross margin pressures with lab COGS rising amid volume growth. Upgrading and servicing NGS sequencers and informatics drives both capex and maintenance, often $5-15M per major facility annually, so tight lab throughput and automation are key to protect margins as reimbursements fall.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad spends heavily on a direct sales force-commissions, travel, and physician-education collateral-running about 18-22% of revenue in 2024 (≈$90-110M on $500M revenue), necessary to drive adoption in a competitive diagnostic market and to open new clinical segments.\u003c\/p\u003e\n\u003cp\u003eMarketing also covers digital campaigns and major medical conferences; convention spend alone was ~$8-12M in 2024 to sustain brand visibility and lead flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and Administrative costs include executive leadership, legal, regulatory compliance, and HR; in molecular diagnostics legal\/compliance can be 8-12% of revenue due to FDA\/CLIA and IP work-e.g., peers report $20-50M annual G\u0026amp;A for mid‑size labs with $250-500M revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eG\u0026amp;A: leadership, legal, compliance, HR\u003c\/li\u003e\n\u003cli\u003eLegal\/compliance: 8-12% of revenue\u003c\/li\u003e\n\u003cli\u003eExample: $20-50M G\u0026amp;A for $250-500M revenue\u003c\/li\u003e\n\u003cli\u003eSupports global operations and IP protection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformation Technology and Data Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining secure, scalable IT drives major costs for Myriad: cloud storage and compute ran about $4.5-6.0M in 2024 for comparable genomics firms, cybersecurity suites and compliance (HIPAA, NIST) add ~15-20% more, and EMR integrations require steady engineering sprints; bioinformatics GPU\/CPU spend rises roughly 25% year-over-year as data volumes double every 18-24 months.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud storage \u0026amp; compute: $4.5-6.0M (2024 comparable)\u003c\/li\u003e\n\u003cli\u003eCybersecurity\/compliance: +15-20% of IT spend\u003c\/li\u003e\n\u003cli\u003eEMR integration: ongoing engineering costs\u003c\/li\u003e\n\u003cli\u003eBioinformatics processing: +25% YoY; data doubles 18-24 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: Heavy R\u0026amp;D (20-30%), rising COGS (25-40%), sales 18-22%, IT\/security up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad allocates ~20-30% of operating budget to R\u0026amp;D ($160-240M on $800M-$1B), COGS ~25-40% of revenue with lab OPEX rising, sales ~18-22% (~$90-110M on $500M), G\u0026amp;A 8-12% (example $20-50M), IT\/cloud ~$4.5-6M plus 15-20% security; bioinformatics compute +25% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$160-240M (20-30%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e25-40% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e$90-110M (18-22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$20-50M (8-12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\u003c\/td\u003e\n\u003ctd\u003e$4.5-6M +15-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Diagnostic Testing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest revenue stream is hereditary cancer testing and companion diagnostics sold to oncology practices, accounting for roughly 60% of Myriad Genetics' test revenue in 2024-about $520 million of total test revenue of $870 million reported in FY2024. These tests are paid per test by insurers or health systems; growth is driven by wider adoption of personalized medicine and broadened testing guidelines, which increased test volume ~8% year-over-year in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacogenomics Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacogenomics product sales center on Myriad's GeneSight test, which generated about $310 million in revenue in FY2024 and helps clinicians tailor psychiatric meds to reduce trial-and-error. Payer coverage rose to roughly 60% of US lives by end-2024, supporting recurring revenue given ~20% lifetime prevalence of major depressive disorder and strong clinical utility shown to cut treatment failures and costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen Health Testing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpwomen health testing services generates revenue from non-invasive prenatal carrier screening and related reproductive genetic tests sold primarily through ob-gyn channels nipt worldwide market reached in with cagr typical per-test prices range depending on panel depth. volume ties to birth rates fertility births rising standard-of-care: by of us pregnancies receive boosting predictable recurring lab revenue.\u003e\n\u003c\/pwomen\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion Diagnostic Development Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad earns B2B revenue from biopharma partners via service agreements for companion diagnostic development and validation, collecting upfront fees, clinical milestone payments, and royalties at commercial launch; in 2024 Myriad reported diagnostics services contributing roughly $85M, buffering patient-volume volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees for assay development\u003c\/li\u003e\n\u003cli\u003eMilestones during trials (per-phase payments)\u003c\/li\u003e\n\u003cli\u003eRoyalties on diagnostic sales\u003c\/li\u003e\n\u003cli\u003e2024 services revenue ~ $85M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Data Collaboration Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company earns revenue by licensing proprietary assays and algorithms and by granting access to anonymized genomic datasets for research; in 2024 licensing\/data collaborations contributed about 6-8% of total revenue, a high-margin segment with gross margins above 70%.\u003c\/p\u003e\n\u003cp\u003eThese deals with universities and pharma tap Myriad's \u0026gt;3.5 million-patient database, accelerating publications and drug-target discovery while scaling non-dilutive income.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 share: ~6-8% of revenue\u003c\/li\u003e\n\u003cli\u003eEstimated gross margin: \u0026gt;70%\u003c\/li\u003e\n\u003cli\u003eDatabase size: \u0026gt;3.5 million patients (2024)\u003c\/li\u003e\n\u003cli\u003eCustomers: academic labs, biotech, Big Pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad FY24: $870M tests-Hereditary cancer $520M, GeneSight $310M, data licensing high-margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's FY2024 revenues: hereditary cancer testing ~$520M (60% of $870M test revenue), GeneSight ~$310M, women's health\/NIPT growth with global NIPT market $4.2B (2024), diagnostics services ~$85M, licensing\/data 6-8% (gross margin \u0026gt;70%), database \u0026gt;3.5M patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHereditary cancer\u003c\/td\u003e\n\u003ctd\u003e$520M (60%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003e$310M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/data\u003c\/td\u003e\n\u003ctd\u003e6-8% rev, \u0026gt;70% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354796106059,"sku":"myriad-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/myriad-canvas-business-model.webp?v=1779151511","url":"https:\/\/valuechainanalysis.com\/products\/myriad-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}